Breast Cancer (BC) is the most frequently diagnosed malignancy and the second leading cause of cancer-related death among women. Nowadays two distinct BC subtypes represent a critical clinical challenge: 1) HER2+ BC and 2) Triple Negative BC (TNBC). The former is currently treated by targeted anti-HER 2 antibodies, but it is characterized by the frequent onset of resistance leading to disease recurrence. The TNBC displays heterogeneity, immunogenicity and poor prognosis and no targeted therapy is currently available. Hence, both BC subtypes are treated with cytotoxic chemotherapy combined (HER2+-BC) or not (TNBC) with other targeted drugs [1] .
